The studies will assess the safety and anti-tumour activity of the combined therapy in Chinese patients. Credit: Sai Thaw Kyar / Shutterstock.com.

Innovent Biologics and RemeGen have entered a clinical trial collaboration to evaluate the combination therapies of TYVYT (sintilimab injection) along with antibody-drug conjugates (ADC) RC88 or RC108 for the treatment of advanced solid tumours in China.

As part of the deal, Innovent will supply TYVYT while RemeGen will carry out Phase I/IIa studies of the combination therapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The studies will assess the safety and anti-tumour activity of the combined therapy in Chinese patients with advanced solid tumours.

RC88 includes an MSLN antibody moiety and RC108 is a c-MET targeting antibody.

Preliminary results of both ADCs showed anti-tumour activity and a manageable safety profile.

Innovent Biologics senior vice-president Dr Hui Zhou said: “Preclinical studies have suggested the synergistic anti-tumour effects, which supports the investigation of combining ADCs with an anti-PD-1 monoclonal antibody to improve patient outcomes and overcome drug resistance.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“As immunotherapy advanced into the next era of development, we hope to strengthen the leading position of sintilimab as a backbone immunotherapy as well as investigate the new opportunities of combination therapies, and provide better treatment options for more cancer patients.”

Co-developed by Innovent along with Eli Lilly and Company, sintilimab has been approved for seven indications in China, including hepatocellular carcinoma, gastric cancer, oesophagal squamous cell carcinoma, and non-squamous and squamous NSCLC.

RemeGen senior vice-president Na Su said: “Collaborating with Innovent is an important advancement in the research and commercialisation strategy for the combination therapy of RC88 and RC108.  

“The combination of RC88 and RC108 with sintilimab provides an innovative treatment approach that targets two different targets simultaneously.”